Maria G Crespo-Leiro1, Stefan D Anker2, Aldo P Maggioni3,4, Andrew J Coats5, Gerasimos Filippatos6, Frank Ruschitzka7, Roberto Ferrari8, Massimo Francesco Piepoli9, Juan F Delgado Jimenez10, Marco Metra11, Candida Fonseca12, Jaromir Hradec13, Offer Amir14, Damien Logeart15, Ulf Dahlström16, Bela Merkely17, Jaroslaw Drozdz18, Eva Goncalvesova19, Mahmoud Hassanein20, Ovidiu Chioncel21, Mitja Lainscak22, Petar M Seferovic23, Dimitris Tousoulis24, Ausra Kavoliuniene25, Friedrich Fruhwald26, Emir Fazlibegovic27, Ahmet Temizhan28, Plamen Gatzov29, Andrejs Erglis30, Cécile Laroche3, Alexandre Mebazaa31. 1. Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Complexo Hospitalario Universitario A Coruna, CHUAC, La Coruna, Spain. 2. Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany. 3. EURObservational Research Programme, European Society of Cardiology, Sophia-Antipolis, France. 4. ANMCO Research Centre, Florence, Italy. 5. Monash University, Australia and University of Warwick, Coventry, UK. 6. Athens University Hospital Attikon, Athens, Greece. 7. Department of Cardiology, Heart Failure Clinic and Transplantation, University Heart Centre Zurich, Zurich, Switzerland. 8. Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care and Research, ES Health Science Foundation, Cotignola, Italy. 9. Heart Failure Unit, Cardiac Department, Guglielmo da Saliceto Hospital, AUSL Piacenza, Italy. 10. Cardiology Department, University Hospital 12 de Octubre, Madrid, Spain. 11. Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. 12. Heart Failure Unit, S Francisco Xavier Hospital/CHLO NOVA Medical School, Faculdade de Ciências Medicas, Universidade Nova de Lisboa, Portugal. 13. 3rd Department of Medicine, Faculty General Hospital, Charles University, Prague, Czech Republic. 14. Poriya Medical Centre and Faculty of Medicine Bar Ilan University, Israel. 15. Assistance Publique Hôpitaux Paris, Hôpital Lariboisière, Université Paris Diderot, Inserm 942, Paris, France. 16. Department of Cardiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 17. Semmelweis University, Heart Centre, Budapest, Hungary. 18. Department of Cardiology, Medical University of Lodz, Lodz, Poland. 19. Department of Heart Failure/Transplantation, National Cardiovascular Institute, Bratislava, Slovakia. 20. Alexandria University, Alexandria, Egypt. 21. Institutul De Urgente Boli Cardiovasculare CC Iliescu, Universitatea de Medicina Carol Davila, Bucuresti, Romania. 22. Department of Cardiology, General Hospital Celje, Celje, Slovenia. 23. University of Belgrade, School of Medicine, Department of Cardiology, Clinical Centre of Serbia. 24. 1st Cardiology Department, Athens University Medical School, Athens, Greece. 25. Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 26. Department of Cardiology, Medical University, Graz, Austria. 27. Department of Internal Medicine, Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina. 28. Turkey Yüksek Ihtisas Hospital, Cardiology Clinic, Ankara, Turkey. 29. University Hospital Lozenets, Sofia, Bulgaria. 30. Pauls Stradins Clinical University Hospital, Riga, Latvia. 31. Hôpital Lariboisière, Université Paris Diderot, Inserm 942, Paris, France.
Abstract
AIMS: The European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT-R) was set up with the aim of describing the clinical epidemiology and the 1-year outcomes of patients with heart failure (HF) with the added intention of comparing differences between participating countries. METHODS AND RESULTS: The ESC-HF-LT-R is a prospective, observational registry contributed to by 211 cardiology centres in 21 European and/or Mediterranean countries, all being member countries of the ESC. Between May 2011 and April 2013 it collected data on 12 440 patients, 40.5% of them hospitalized with acute HF (AHF) and 59.5% outpatients with chronic HF (CHF). The all-cause 1-year mortality rate was 23.6% for AHF and 6.4% for CHF. The combined endpoint of mortality or HF hospitalization within 1 year had a rate of 36% for AHF and 14.5% for CHF. All-cause mortality rates in the different regions ranged from 21.6% to 36.5% in patients with AHF, and from 6.9% to 15.6% in those with CHF. These differences in mortality between regions are thought reflect differences in the characteristics and/or management of these patients. CONCLUSION: The ESC-HF-LT-R shows that 1-year all-cause mortality of patients with AHF is still high while the mortality of CHF is lower. This registry provides the opportunity to evaluate the management and outcomes of patients with HF and identify areas for improvement.
AIMS: The European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT-R) was set up with the aim of describing the clinical epidemiology and the 1-year outcomes of patients with heart failure (HF) with the added intention of comparing differences between participating countries. METHODS AND RESULTS: The ESC-HF-LT-R is a prospective, observational registry contributed to by 211 cardiology centres in 21 European and/or Mediterranean countries, all being member countries of the ESC. Between May 2011 and April 2013 it collected data on 12 440 patients, 40.5% of them hospitalized with acute HF (AHF) and 59.5% outpatients with chronic HF (CHF). The all-cause 1-year mortality rate was 23.6% for AHF and 6.4% for CHF. The combined endpoint of mortality or HF hospitalization within 1 year had a rate of 36% for AHF and 14.5% for CHF. All-cause mortality rates in the different regions ranged from 21.6% to 36.5% in patients with AHF, and from 6.9% to 15.6% in those with CHF. These differences in mortality between regions are thought reflect differences in the characteristics and/or management of these patients. CONCLUSION: The ESC-HF-LT-R shows that 1-year all-cause mortality of patients with AHF is still high while the mortality of CHF is lower. This registry provides the opportunity to evaluate the management and outcomes of patients with HF and identify areas for improvement.
Authors: Elena-Laura Antohi; Andrew P Ambrosy; Sean P Collins; Ali Ahmed; Vlad Anton Iliescu; Gad Cotter; Peter S Pang; Javed Butler; Ovidiu Chioncel Journal: Am J Ther Date: 2019 Mar/Apr Impact factor: 2.688
Authors: Madalena Coutinho Cruz; Ana Abreu; Guilherme Portugal; Helena Santa-Clara; Pedro S Cunha; Mario M Oliveira; Vanessa Santos; Luís Oliveira; Pedro Rio; Inês Rodrigues; Luís A Morais; Rui C Ferreira; Miguel M Carmo Journal: J Nucl Cardiol Date: 2017-12-05 Impact factor: 5.952